Apixaban + Cofact (4-Factor PCC) + Beriplex P/N (4-Factor PCC) + Placebo (Saline solution)
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anticoagulation
Conditions
Anticoagulation
Trial Timeline
Feb 1, 2014 → Apr 1, 2014
NCT ID
NCT02074358About Apixaban + Cofact (4-Factor PCC) + Beriplex P/N (4-Factor PCC) + Placebo (Saline solution)
Apixaban + Cofact (4-Factor PCC) + Beriplex P/N (4-Factor PCC) + Placebo (Saline solution) is a phase 1 stage product being developed by Bristol Myers Squibb for Anticoagulation. The current trial status is completed. This product is registered under clinical trial identifier NCT02074358. Target conditions include Anticoagulation.
What happened to similar drugs?
2 of 4 similar drugs in Anticoagulation were approved
Approved (2) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02074358 | Phase 1 | Completed |
Competing Products
7 competing products in Anticoagulation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apixaban | Pfizer | Approved | 43 |
| VKA + Apixaban + dabigatran + rivaroxaban | Bristol Myers Squibb | Pre-clinical | 26 |
| Apixaban | Bristol Myers Squibb | Pre-clinical | 26 |
| four factor prothrombin complex concentrate | CSL | Approved | 39 |
| DOACs: Rivaroxaban, Dabigatran, Apixaban + Standard of care (Warfarin) | Bayer | Pre-clinical | 23 |
| Prismocitrate 18 | Baxter | Phase 3 | 44 |
| Prismocitrate 18 | Baxter | Phase 3 | 29 |